Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers

Significantly Strengthens Intellectual Property Portfolio and Apabetalone’s Commercial Runway Position Through 2040

BETonMACE Results Show Significant Improvement of Key Markers of Diabetes and Renal Function in the Combination of Apabetalone and SGLT2 inhibitors

CALGARY, Alberta, Nov. 02, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased to announce today highly significant findings on synergy on improved renal function, as measured by estimated glomerular filtration rate (eGFR), and glucose control, as measured by glycated hemoglobin (HbA1c), when apabetalone is combined with sodium-glucose cotransporter-2 (SGLT2) inhibitors, a leading oral anti-diabetic therapy class. These unexpected findings in the BETonMACE Phase 3 trial resulted in the filing of two additional provisional patent applications, further strengthening Resverlogix’s intellectual property portfolio.

The combination of apabetalone and the SGLT2 inhibitors, in addition to standard of care medicines, resulted in a significant improvement of key renal function marker eGFR compared to SGLT2 inhibitors and placebo (p=0.05). Additionally, a significant reduction of plasma Hb1Ac was also observed in patients receiving the combination of apabetalone and the SGLT2 inhibitors, on top of standard of care treatment, compared to placebo (p<0.001). Details of these findings are planned to be submitted to a leading peer review journal in the near future.

“The robust safety and efficacy demonstrated by the combination of apabetalone and SGLT2 inhibitors greatly assists us in our strategic partnership discussions and significantly enhances our intellectual property portfolio and commercial runway position through 2040,” stated Donald McCaffrey, President and CEO. “These important findings – coupled with the significant MACE reduction effects previously highlighted for this patient group – positions the combination of apabetalone and SGLT2 inhibition as a truly novel approach in the treatment for millions of high-risk diabetes and CKD patients worldwide.”

“Plasma eGFR and Hb1Ac are critical markers used to evaluate renal function and glucose control in high-risk patients with kidney disease and diabetes,” stated Kenneth Lebioda, Senior Vice President of Business & Corporate Development. “Control of these markers play a key role in CVD risk reduction as observed in the BETonMACE study, including heart attack, heart failure and CVD death in these patients. These novel and unexpected findings are now patent protected and allow for Resverlogix to explore additional important indications for the combination of apabetalone and SGLT2 inhibitors with an accelerated path to commercialization.”

About eGFR and CKD

According to the National Kidney Foundation, renal function, as measured by eGFR is the strongest non-invasive way to assess renal function and the stage of chronic kidney disease (CKD) in patients. Using a patient’s blood creatinine level, age, body size and gender, physicians can determine the stage of CKD and the optimal treatment plan to improve the likelihood of reducing kidney disease and associated-disorders progression. In the Global Burden of Disease Study, CKD is estimated to affect nearly 700 million people worldwide, many of them still undiagnosed. CKD and worsening renal function impact several other high-risk patient disease groups, and serves as a comorbidity for diabetes, while also indirectly

Read more

Global Tumor Infiltrating Lymphocytes TIL Immunotherapy Markers Market Size Research Companies Clinical Trials Outlook Report 2025

Tumor Infiltrating Lymphocytes Therapy To Transform The Global Immunotherapy Market Over next Decade Says Kuick Research

DELHI, India, Oct. 22, 2020 (GLOBE NEWSWIRE) — “Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025” Report Highlights:

  • Tumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies

  • Highest Phase of Development for Tumor Infiltrating Lymphocytes Immunotherapy : Phase II Trials

  • USA To Dominate Global Tumor Infiltrating Lymphocytes Immunotherapy Market Landscape

  • Expected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000

  • TIL Therapy Can Drive Personalized Cancer Therapy Market

Download Report:

https://www.kuickresearch.com/report-global-tumor-tnfiltrating-lymphocytes-immunotherapy-therapy-til-market-size-sales-clinical-trials-lifileucel-ln144-ln145-tilt123

The tumor-infiltrating lymphocyte therapy market is a potent immunotherapy available for the cancer patients but the survival of the therapy in a market where there are plenty of other immunotherapies was not easy. The therapy in a short period of time has made its way through from all the challenges and led to a stage where the availability of the therapy is highly appreciated and praised. The therapy when compared with the other available therapies such as immune checkpoint therapy and monoclonal antibodies is delivering some of the applications that are not observed for other therapies. An important application or advantage of the therapy over the other therapies is the inclination of the tumor-infiltrating lymphocyte therapy market towards personalized therapy. In today’s generation, arrival of personalized therapy is highly appreciated as it has led to an overall survival rate that is more than ever in the past few decades. Also, the therapy has provided the patients with the treatment that is highly required.

All the recent developments that have been characterized have made the therapy produce durable response against the different types of cancer that are prevalent in the patients. Tumor-infiltrating lymphocyte therapy market, above all the therapies that are available is estimated to produce stronger immune response as the technical approach that is coupled with the therapy at laboratory levels are tremendous and fascinating. Being novel and innovative have also led to the arrival of the therapy as a top and pioneering frontier for the pharmaceutical industry.

In the overall development and expansion of the market at a level that is higher than most of the dominating markets of the world, many major research centers and advanced organizations such as National Institute of Health are demonstrating research activity work that is unmatchable with any other ongoing work for other therapies. The market has also achieved a high status when referred to the number of publications that it has done in the past few years. The number of published papers that carry different applications of the therapy has increased multiple times in the past few years. This however indicates the interest of the researchers and the physicians in making the therapy full time available for the cancer patients.

Research work such as the use of TILs in various different cancer types also demonstrated that the combination of autologous TIL and cyclophosphamide could induce regression of metastases and many others have helped the market to establish a landmark in the

Read more